89bio Inc (ETNB)
8.75
+0.24
(+2.82%)
USD |
NASDAQ |
May 01, 16:00
8.73
-0.02
(-0.23%)
Pre-Market: 20:00
89bio Enterprise Value: 279.14M for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 01, 2024 | 279.14M |
| April 30, 2024 | 256.29M |
| April 29, 2024 | 258.19M |
| April 26, 2024 | 232.48M |
| April 25, 2024 | 231.53M |
| April 24, 2024 | 262.95M |
| April 23, 2024 | 295.33M |
| April 22, 2024 | 332.47M |
| April 19, 2024 | 310.57M |
| April 18, 2024 | 291.52M |
| April 17, 2024 | 318.18M |
| April 16, 2024 | 338.18M |
| April 15, 2024 | 349.61M |
| April 12, 2024 | 381.03M |
| April 11, 2024 | 411.50M |
| April 10, 2024 | 449.59M |
| April 09, 2024 | 483.87M |
| April 08, 2024 | 473.40M |
| April 05, 2024 | 470.54M |
| April 04, 2024 | 460.07M |
| April 03, 2024 | 481.02M |
| April 02, 2024 | 453.40M |
| April 01, 2024 | 467.69M |
| March 28, 2024 | 534.28M |
| March 27, 2024 | 503.42M |
| Date | Value |
|---|---|
| March 26, 2024 | 493.14M |
| March 25, 2024 | 506.23M |
| March 22, 2024 | 521.19M |
| March 21, 2024 | 516.51M |
| March 20, 2024 | 504.36M |
| March 19, 2024 | 560.46M |
| March 18, 2024 | 624.04M |
| March 15, 2024 | 710.06M |
| March 14, 2024 | 624.98M |
| March 13, 2024 | 690.43M |
| March 12, 2024 | 649.29M |
| March 11, 2024 | 651.16M |
| March 08, 2024 | 654.90M |
| March 07, 2024 | 663.31M |
| March 06, 2024 | 580.09M |
| March 05, 2024 | 542.69M |
| March 04, 2024 | 733.44M |
| March 01, 2024 | 625.91M |
| February 29, 2024 | 518.38M |
| February 28, 2024 | 545.50M |
| February 27, 2024 | 543.63M |
| February 26, 2024 | 477.24M |
| February 23, 2024 | 491.27M |
| February 22, 2024 | 436.10M |
| February 21, 2024 | 423.95M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-64.08M
Minimum
May 09 2022
1.149B
Maximum
Jun 13 2023
317.59M
Average
268.50M
Median
Mar 30 2021
Enterprise Value Benchmarks
| Madrigal Pharmaceuticals Inc | 3.661B |
| Akero Therapeutics Inc | 859.42M |
| Viking Therapeutics Inc | 7.465B |
| Galectin Therapeutics Inc | 264.97M |
| Terns Pharmaceuticals Inc | 65.64M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -40.24M |
| Total Expenses (Quarterly) | 41.21M |
| EPS Diluted (Quarterly) | -0.50 |
| Earnings Yield | -22.97% |